Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

BiVictriX Therapeutics to "continue seeking out positive relationships"

BiVictriX Therapeutics PLC

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) founder and CEO Tiffany Thorn speaks to Proactive after releasing full year results for 2022, a year that she describes as "very good" for the UK-based drug discovery and development company. Thorn reveals what she was most pleased with from the year before turning her focus to her priorities for 2023, highlighting a desire to grow the company's profile and to "continue seeking out positive relationships." Here's more on that story: BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) has said it is focused on three value creation points for its lead asset BVX001, which is being developed to treat acute myeloid leukaemia. In working towards these goals it believes it will attract the attention of potential partners for what could eventually be a blockbuster treatment. It also reckons this work will provide validation for its Bi-Cygni platform, which aims to develop targeted cancer drugs with fewer side effects. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 30, 2023 05:20 AM Eastern Daylight Time

Video

Poolbeg Pharma "in a very healthy cash position" after first full year of operations

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full year of operations with £16.2mln. Skillington describes it as a "very healthy cash position" and summarises his main highlights from the year, before looking ahead to what the market can expect from Poolbeg during the rest of 2023. Here is the earlier story: Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has said it is working towards its first partnering ‘transaction’ for POLB 001 after a successful period in which it conducted a first human challenge study on its lead asset to assess its potential in severe flu. On its own, this would be a significant achievement. However, the drug developer has been active in broadening its pipeline in 2022 – adding POLB 002 for severe respiratory virus infections and POLB 003 for melioidosis. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 30, 2023 04:08 AM Eastern Daylight Time

Video

There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study

Coya Therapeutics Inc.

By David Willey, Benzinga Coya Therapeutics (NASDAQ: COYA) has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS). The results for this novel biologic were positive, showing a slowing or even halting of ALS’ progression. There is currently no drug on the market that can halt ALS progression. The global market for ALS treatment was worth $613 million in 2022 and is expected to reach $1.03 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period. There is no known cure for ALS, and the increasing awareness of the disease raised by healthcare and advocacy organizations is partly behind the current market growth. Also known as Lou Gehrig’s disease, ALS can either be hereditary or individual. While it is most associated with aging, certain unhealthy environments and lifestyles could also factor in increasing rates of ALS incidence. ALS is a disease that attacks the brain and spinal column, destroying the motor neurons and causing the degeneration of the nervous system. It usually starts at the extremities like the hands or feet, and as it spreads the patient loses control of their muscles, normally dying from respiratory failure within three to five years. Familial or hereditary ALS only accounts for 5-10% of all ALS patients, and the cause of ALS in sporadic patients, up to 95%, is still unknown. Drugs that are currently on the market, such as Radicava (Edaravone) or Amylyx’s Relyvrio, may slow but do not stop the disease. Recent research suggests that perhaps the best way to tackle ALS is through immunomodulatory therapy that targets motor neuron disease by attacking inflammatory and oxidative stress pathways, which are thought to be contributing to neuronal dysfunction. This is Coya Therapeutics’s approach with its biologic, COYA 302. Data Results Suggest COYA 302 Could Be The Answer Through the data that Coya has collected in its proof of concept study, it believes COYA 302 can control or even possibly even prevent ALS decline. COYA 302 is an investigational combination biologic administered subcutaneously, and it is a combination of COYA 301 (low dose IL-2) and CTLA4-Ig fusion protein. The drug’s dual action controls both inflammation and oxidative stress in the blood. It supports the regulatory T-cells (Treg), which control the immune system’s inflammatory response, and downregulates effector cells, proinflammatory cells, and lipid peroxides. Over the clinical trial’s 48-week period, the drug was tested on four patients for safety, tolerability, the function of Tregs, certain biomarkers, and also for preliminary efficacy. At 24 weeks, there was significant Treg enhancement, and at 48 weeks the serum biomarkers for inflammation and oxidative stress were lowered. Throughout the treatment, the patients did not appear to suffer any serious adverse effects. COYA 302’s preliminary efficacy was measured using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), a validated rating tool that monitors the disability progression in ALS patients. The mean (±SD) ALSFRS-R scores were 33.75 ±3.3 at week 24 and 32 ±7.8 at week 48, not statistically different from the ALSFRS-R score at baseline (33.5 ±5.9) before COYA 302 treatment. In other words, the data suggests a significant improvement in the progression of the disease over the 48-week treatment period, validating Coya’s approach with its new biologic. “We believe the results of this initial proof-of-concept study in a small number of ALS patients are encouraging and warrant conducting a larger and controlled industry-sponsored study. ALS continues to be a disease of high unmet need and we are committed to develop COYA 302 as safely and as expeditiously as possible, in compliance with current regulations,” said Adrian Hepner, M.D., Coya’s Chief Medical Officer. “We plan to file an IND with the FDA in the second half of 2023 and initiate a clinical study soon thereafter.” Want to learn more about Coya Therapeutics and what it’s doing to treat ALS? Visit its website. This article was originally published on Benzinga here. About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

March 29, 2023 09:00 AM Eastern Daylight Time

News Release

FREEDOM HOLDINGS ANNOUNCES MANAGEMENT HAS COMPLETED FINANCIAL REPORTS

FREEDOM HLDG INC.

McapMediaWire -- Freedom Holdings, Inc. aka Freedom Acquisition Corp (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce that new management has completed the 10Q and 10K filings bringing the company audits and filings current and up to date for fiscal year ending September 30, 2022. John Vivian, CEO stated: “We are now working on the remaining 10Q for period ending 12-31-2022 and once completed will be fully SEC compliant. This will then allow management to work towards the approval of trading status. I am happy to further report that the company is in substantive negotiations with several cannabis companies to acquire and merge under the Freedom umbrella in execution of the Company business plan." "We look forward to bringing new and exciting updates of the furtherance of our efforts in the very near future", concluded Vivian. Press Release Contact: John Vivian CEO Freedom Holdings, Inc. 813-699-4098 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details Freedom Holdings, Inc. +1 813-699-4098

March 29, 2023 08:30 AM Eastern Daylight Time

Orange Tree Employment Screening Accelerates Momentum with Expansion of Senior Leadership Team

Orange Tree Employment Screening

Orange Tree Employment Screening, a technology-driven services company in the background screening industry, today announced that it has expanded its leadership team to include three new senior roles. Justin Jovle will serve as the new Chief Operating Officer (COO), while Bridget George will be the new Vice President of Client Services, and Brooke Boeser will help guide company expansion as the new Vice President of Marketing. The new hires will help the company continue to accelerate its strong growth while delivering unparalleled client service. “Over the past 18 months, Orange Tree has grown significantly, both organically and through acquisition. To continue this growth, it is important to strategically expand our leadership team,” said Renee Ernste, CEO of Orange Tree. “We are not stopping here. We have expansion plans which require expertise to enable the successful integration of the companies we’ve purchased and to support future acquisitions.” In addition to growing via acquisition and new sales, Orange Tree recently released an innovative online buying experience which provides buyers new levels of choice and pricing transparency. Available to all businesses, the online platform is targeted to the midmarket and small business customer who wants help in choosing the best solution with full visibility to pricing previously reserved for only enterprise businesses. “The buyers’ preferences have changed, and we are delivering what today’s customer expects and deserves,” said Jeff Ernste, Chief Sales and Marketing Officer. “Customers want to buy solutions tailored to their needs, in a way and at a time that is convenient for them, and with full transparency to the pricing and terms of their program. We are delivering a solution which aligns precisely with their needs. “The strategic decision to bring in tested leadership and launch a game-changing online buying platform means that Orange Tree’s growth momentum is just beginning,” concluded Ernste. About Orange Tree Employment Screening For more than 30 years, Orange Tree has provided technology-enabled background screening, drug testing, and occupational health services that are fast, easy to use, and can be tailored to the unique needs of each employer. Orange Tree streamlines hiring decisions, integrates with HCM and ATS platforms, and empowers employers in Healthcare, Manufacturing, Hospitality, Retail, Staffing, and other major industries to quickly fill open positions while delivering an engaging candidate experience. Learn more at www.orangetreescreening.com. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.orangetreescreening.com/

March 28, 2023 08:30 AM Central Daylight Time

NAVEX 2023 Global Incident Management Benchmark Study Reveals Shifts in Workplace Culture and Reporting Trends

NAVEX Global

NAVEX, the leader in integrated risk and compliance management software, has released its 2023 Hotline & Incident Management Benchmark Report. The bellwether annual benchmark report provides valuable insight into the workplace culture of 52 million employees across 3,430 organizations, examining the trends of 1.52 million reports from across the globe. "We use NAVEX's annual benchmark report to help inform our risk management strategy," says FedEx Chief Compliance Officer Justin Ross. "As an industry leader, we do our best to stay ahead of the curve when it comes to the latest incident reporting and risk management trends. The insight this report provides helps us do just that." “NAVEX has long been the gold standard for risk and compliance data analytics in the industry. This annual benchmark study is derived from the world’s largest incident reporting database by far,” says Carrie Penman, NAVEX chief risk and compliance officer. “Our expanded analytics in 2023 allowed for a deeper examination of the issues and behaviors that are most impactful to today’s workplaces. Chief among them is workplace civility, which is likely driven by increased societal tension generally.” This year’s analysis of the data revealed four key themes and several notable findings: Reporting at an all-time high, but reporters proceeded with more caution. This year’s analysis revealed the highest median level of Reports per 100 Employees (1.47) in the history of this report. Further, 21% of organizations received five or more Reports per 100 Employees, a positive finding. However, data also showed a return to higher levels of anonymous reporting (56%), indicating more reporter concern about providing their name. HR-related reports are still the majority, but more granular analysis reveals workplace stresses. The median organization had nearly 54% of its reports in the HR, Diversity & Workplace Respect category, up from 50% in 2021. Reviewing the reporting frequency across deeper issue types offers more insight into organizational stresses and behaviors – particularly an increase in workplace civility concerns involving abusive or disrespectful behavior. The data also shows the frequency of harassment, discrimination, retaliation, and substance abuse reports in 2022 all increased. These metrics are important to watch as a measure of cultural health and potentially a measure of mental health risks. People want to talk live, but a written web-based report is more likely to be substantiated. While general communications modes move more to texting and instant messaging, this year's data shows an increase in telephonic helpline reports, from 31% in 2021 to 34% in 2022. Hybrid work models have made it easier for employees to make a telephone report from home and more challenging to report in person. However, more thoughtful written reports, submitted via the web, are more likely to be substantiated than phone reports. In 2022, the median Substantiation Rate for web reports was 39% compared to 33% for phone. Size matters – smaller organizations have higher reporting rates; mid-size companies are experiencing some challenges. The 2022 analysis reveals that smaller organizations with fewer than 2,500 employees registered the highest Reports per 100 Employees at 2.99. In contrast, the largest organizations, with over 100,000 employees, had a much lower rate of only 1.20 Reports per 100 Employees. Mid-sized companies with 2,500-49,999 employees had the lowest rate of all, with fewer than 1.0 Reports per 100 Employees. Organizations with 2,500 to 5,999 employees recorded the highest rate of anonymous reporting at 60%. "Data is at the heart of making smart decisions about risk management and spotting potential problems throughout the organization. This is particularly important for issues affecting workplace culture. NAVEX's integrated data platform provides industry-leading insights and a unique window into the performance of their risk and compliance program, which in turn helps them achieve the business outcomes that matter most," says A.G. Lambert, NAVEX chief product officer. Additional notable findings include: The frequency of bribery and corruption reports increased in 2022, as did product quality and safety reports. Conflicts of interest reporting dropped significantly but is still in the top five. Data privacy and protection also made the top five. While overall Substantiation Rates remained steady at 41%, the five issue types with the highest frequency of substantiation were: global trade (76%), imminent threat to a person or property (75%), environment (71%), Data privacy and protection (68%), misuse or misappropriation of assets (67%) and health and safety (65%). More than half of organizations have a median Case Closure Time under 30 days. The largest organizations had the shortest Case Closure Time. Notable, and perhaps concerning, is a median of 18% of cases were closed on the same day they were received. This finding indicates instances that may have been forwarded to a different department and resolved prior to complete resolution, implying that a case classified as "closed" for compliance does not necessarily denote closure for the organization. For more insights on the 2023 Incident Management Benchmark Report, join Justin Ross, FedEx chief compliance officer, Carrie Penman, NAVEX chief risk & compliance officer, and Anders Olsen, NAVEX senior data scientist, for an informative webinar where they will discuss the results of this year’s analysis in detail. Register here or, read our blog, Don’t Miss Out – World’s Leading Hotline Webinar & Report Released March 28. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details NAVEX Scott Levesque +1 617-388-5773 scott.levesque@navex.com Company Website https://www.navex.com

March 28, 2023 08:30 AM Eastern Daylight Time

Image

News Release

Lucy Scientific Discovery signs definitive agreement to acquire Wesana Health

Lucy Scientific Discovery Inc.

Lucy Scientific Discovery CEO Chris McElvany and Wesana CEO Dan Carcillo joined Steve Darling from Proactive to share news the company has signed a definitive agreement to purchase the assets of Wesana Health. McElvany tells Proactive more about the decision to acquire the company and more specifically about its psilocybin and CBD combination investigational therapy, SANA-013. Carcillo talks more about SANA-013 and the works they have been doing. He also talks about what his role will be on the Lucy management team. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

March 27, 2023 12:49 PM Eastern Daylight Time

Video

Why Are People So Afraid of Root Canals?

YourUpdateTV

Root canals tend to strike fear in people. Just thinking of the words are enough to terrify most of us. Root canal symptoms can be a pain. Choosing your root canal option doesn’t have to be. According to the Journal of Family Medicine and Primary Care, 2020, many people actually avoid root canals and further deteriorate the state of their teeth purely because they have misconceptions about the pain and treatment time associated with the procedure. However, root canal treatment can be extremely important – in fact, dental research shows that losing teeth can result in psychological distress due to lowered self-confidence, especially if the lost teeth are highly visible. To combat these fears and misconceptions, the GentleWave Procedure is a less invasive and less painful alternative to conventional root canal treatment. It is redefining standard treatment with a minimally invasive process that preserves tooth structure and promotes early healing. Focused on saving teeth, Sonendo is a commercial-stage medical technology company and the developer of the GentleWave System. According to a recent clinical trial, 99.5% of patients experienced minimal to no pain during the GentleWave Procedure with the addition of CleanFlow Technology. More than one million patients have received the GentleWave Procedure to date. Sonendo is leveraging its innovative technology to transform root canal therapy, making it simpler for clinicians and less invasive and almost pain-free for patients. For more information on the GentleWave System visit: GENTLEWAVE.COM Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 27, 2023 11:00 AM Eastern Daylight Time

Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?

DSS, Inc.

By Ernest Dela Aglanu, Benzinga Impact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and conditions and one of the key businesses in the DSS Inc. (NYSE American: DSS) portfolio, is preparing for a potential spinoff that could also have implications for the pharmaceutical industry at large. The success of this spinoff could present significant growth opportunities for the company. It looks to help expand the company’s ownership of a suite of antiviral and medical technologies, which was valued at $390 million in 2019 by Destum Partners, a global leader in investment and advisory services. The total global pharmaceutical market was estimated at $1.48 trillion in 2022 alone, and as the sector continues to experience an upward trend, Impact Biomedical could expect to see growth opportunities. But one may ask, what is the fuss about the company spinning off? A spinoff occurs when a company splits off a portion of its business into a separate company and distributes shares of the new entity tax-free to the parent company’s shareholders. Some prominent companies that have pursued spinoffs recently include 3M Co. (NYSE: MMM), General Electric Company (NYSE: GE), and Johnson & Johnson (NYSE: JNJ). The good news is such a spinoff can increase Impact Biomedical’s valuation — and the value of DSS. In May 2020, Impact Biomedical revealed it had received a valuation of $933 million for a suite of technology from a different independent valuation firm. The valuation may go even higher, possibly presenting exciting opportunities for investors. Overall, the spinoff, which is still in the works, may enhance Impact Biomedical’s research leading to breakthroughs in the development of new treatments for a wide range of diseases, from cancer to infectious diseases. It is anticipated that it will enable the company to focus on its core research and development activities without any distractions resulting in faster innovation and more precise targeting of specific disease pathways. By establishing a new, independent company focused exclusively on its research and development efforts, the spinoff would enable Impact Biomedical to attract new funding and investment to pursue a more aggressive growth strategy as it continues to develop its cutting-edge technologies and groundbreaking research. The spinoff could warrant a close watch, especially as the company says it has established a reputation and loyal following among investors and healthcare professionals. DSS completed the acquisition of Impact BioMedical in August 2020. In September last year, the company dropped hints of the impending spinoff with reports suggesting that the company was expected to file an amended S-1. DSS said it aimed to IPO Impact Biomedical this year, with the valuation to be determined by the investment bankers and market demand. What could be exciting for shareholders is that the company plans to keep at least 50% of the spinoff entity, while shareholders will get a certain percentage. A number of shares will be newly issued to raise capital to support the growth of the newly public company. Since 2019, the company has embarked on a major transformation journey evolving into a multinational business operating within nine divisions with over 40 subsidiaries. The divisions and subsidiaries are meant to offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers but also create sustainable value and opportunities for transformation; Impact Biomedical is an opportunity for an innovative biotech pure play, and DSS is a way to access Impact and other opportunities. The company has reported developing strong footings in biotechnology, product packaging, direct marketing, commercial lending, securities and investment management, alternative trading, digital transformation, secure living and alternative energy. Impact Biomedical’s Products And Development Pipeline Impact Biomedical drives mission-oriented discovery and development to pursue new products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company reports that its biopharmaceutical technologies have the potential to advance treatment in oncology, neurology, and immunology. A closer look at the current products and development pipeline as reported by Zacks Small-Cap Research: LineBacker: Multi-faceted therapeutic platform intended for metabolic, neurologic, cancer and infectious diseases. In July last year, the company executed a license agreement with ProPhase Labs Inc. (NASDAQ: PRPH) for its Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications. Equivir: A compound in antiviral infection treatments. Equivir/Nemovir is a novel blend of FDA Generally Recognized As Safe -eligible natural compounds which have potential antiviral effects with additional potential applications as health supplements or medication. These compounds are sourced from fruits, vegetables, and other natural substances. In June of 2022, Impact BioMedical signed a license agreement with ProPhase Labs to produce and distribute Equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks. Laetose: Laetose technology is derived from a unique combination of sugar and other compounds, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone. It is a sugar alternative that can potentially lower human glycemic indexes. The company believes it is a breakthrough alternative sugar that could combat diabetes. Using Laetose in a daily diet, compared to sugar, could result in lower sugar consumption and lower glycemic index/load. 3F: 3F is a unique formulation of specialized ingredients from botanical sources with the potential effect as an insect repellent and an antimicrobial. It can be used either as a standalone repellent or as an additive in detergents, lotions, shampoo, and other substances to provide mosquito protection. The formulation can also be used as a standalone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics, and other substances. With a successful IPO and spin off of Impact Biomedical, DSS shareholders would begin to realize the benefits of the company’s strategy of building shareholder value by distributing stock dividends through periodic spin offs. This article was originally published on Benzinga here. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

March 27, 2023 09:00 AM Eastern Daylight Time

1 ... 140 141 142 143 144 ... 304